A phase I/II study of oxaliplatin and paclitaxel in patients with non-resectable cancer of the oesophagus and adenocarcinoma of the gastro-oesophageal junction: A study of the Arbeitsgemeinschaft Internistische Onkologie

Cancer Chemotherapy and Pharmacology

Volumn 66, Issue 1, 2010, Pages 191-195

  Kaechele, Volker ^a   Moehler, Markus ^b   Lutz, Manfred P ^c   Von Wichert, Goetz ^a   Eisele, Miriam ^a   Klaus, Jochen ^a   Galle, Peter R ^b   Adler, Guido ^a   Seufferlein, Thomas ^a,d  

^a UNIVERSITY HOSPITAL ULM   (Germany)

^b UNIVERSITY MEDICAL CENTER MAINZ   (Germany)

^c Caritasklinik St Theresia   (Germany)

^d MARTIN LUTHER UNIVERSITY HALLE WITTENBERG   (Germany)

Author keywords

Cancer of the gastro oesophageal junction; Chemotherapy; Oesophageal cancer; Oxaliplatin; Paclitaxel

Indexed keywords

OXALIPLATIN; PACLITAXEL; ANTINEOPLASTIC AGENT; PLATINUM COMPLEX;

ADULT; AGED; ARTICLE; BLOOD TOXICITY; CANCER CONTROL; CANCER GROWTH; CANCER RESEARCH; CANCER SURVIVAL; CARCINOMATOUS PERITONITIS; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DOSE RESPONSE; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG HYPERSENSITIVITY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSPHAGIA; ESOPHAGEAL ADENOCARCINOMA; ESOPHAGEAL SQUAMOUS CELL CARCINOMA; FEBRILE NEUTROPENIA; FEMALE; GASTROINTESTINAL TOXICITY; HAND FOOT SYNDROME; HUMAN; HYPERCALCEMIA; LOWER ESOPHAGUS SPHINCTER; LUNG INFECTION; MALE; MUCOSA INFLAMMATION; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUROPATHY; NEUTROPENIA; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PNEUMONIA; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; SKIN TOXICITY; SURVIVAL TIME; THROMBOCYTOPENIA; TUMOR LOCALIZATION; VOMITING; ADENOCARCINOMA; DISEASE FREE SURVIVAL; ESOPHAGUS TUMOR; MIDDLE AGED; MULTICENTER STUDY; STOMACH TUMOR; TREATMENT OUTCOME;

ADENOCARCINOMA; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; DISEASE-FREE SURVIVAL; ESOPHAGEAL NEOPLASMS; ESOPHAGOGASTRIC JUNCTION; FEMALE; HUMANS; MALE; MIDDLE AGED; ORGANOPLATINUM COMPOUNDS; PACLITAXEL; STOMACH NEOPLASMS; TREATMENT OUTCOME;

EID: 77951930803     PISSN: 03445704     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00280-010-1312-2     Document Type: Article

References (22)

1. Kamangar F, Dores GM, Anderson WF (2006) Patterns of cancer incidence, mortality and prevalence across five continents: defining priorities to reduce cancer disparities in different geographical regions of the world. J Clin Oncol 24:2137-2150. doi:10.1200/JCO.2005.05.2308 (Pubitemid 46655601)
2. Cameron AJ, Romero Y (2000) Symptomatic gastro-oesophageal reflux as a risk factor for oesophageal adenocarcinoma. Gut 46:754-755
3. Cunningham D, Starling N, Rao S, Iveson T, Nicolson M, Coxon F, Middleton G, Daniel F, Oates J, Norman AR (2008) Capecitabine and oxaliplatin for advanced esophagogastric cancer. N Engl J Med 358:36-46
4. Al-Batran SE, Hartmann JT, Probst S, Schmalenberg H, Hollerbach S, Hofheinz R, Rethwisch V, Seipelt G, Homann N, Wilhelm G, Schuch G, Stoehlmacher J, Derigs HG, Hegewisch-Becker S, Grossmann J, Pauligk C, Atmaca A, Bokemeyer C, Knuth A, Jaeger E (2008) Phase III trial in metastatic gastroesophageal adenocarcinoma with fluorouracil, leucovorin plus either oxaliplatin or cisplatin: a study of the AIO. J Clin Oncol 26:1435-1442. doi:10.1200/JCO.2007. 13.9378
5. Ilson DH, Wadleigh RG, Leichman LP, Kelsen DP (2007) Paclitaxel given by a weekly 1-h infusion in advanced oesophageal cancer. Ann Oncol 1:898-902. doi:10.1093/annonc/mdm004 (Pubitemid 47054088)
6. El-Rayes BF, Shields A, Zalupski M, Heilbrun LK, Jain V, Terry D, Ferris A, Philip PA (2004) A phase II study of carboplatin and paclitaxel in oesophageal cancer. Ann Oncol 15:960-965. doi:10.1093/annonc/mdh230 (Pubitemid 39004354)
7. Lorenzen S, Hentrich M, Haberl C, Heinemann V, Schuster T, Seroneit T, Roethling N, Peschel C, Lordick F (2007) Split-dose docetaxel, cisplatin and leucovorin/fluorouracil as first-line therapy in advanced gastric cancer and adenocarcinoma of the gastroesophageal junction: results of a phase II trial. Ann Oncol 18(10):1673-1679
8. Van Cutsem E, Moiseyenko VM, Tjulandin S, Majlis A, Constenla M, Boni C, Rodrigues A, Fodor M, Chao Y, Voznyi E, Risse EL, Ajani JA (2006) Phase III study of docetaxel and cisplatin plus fluorouracil compared with cisplatin and fluorouracil as first-line therapy for advanced gastric cancer: a report of the V325 Study Group. J Clin Oncol 24(31):4991-4997
9. Fujie Y, Yamamoto H, Ngan CY, Takagi A, Hayashi T, Suzuki R, Ezumi K, Takemasa I, Ikeda M, Sekimoto M, Matsuura N, Monden M (2005) Oxaliplatin, a potent inhibitor of survivin, enhances paclitaxel-induced apoptosis and mitotic catastrophe in colon cancer cells. Jpn J Clin Oncol 35(8):453-463
10. Gu J, Yamamoto H, Lu X, Ngan CY, Tsujino T, Konishi K, Takemasa I, Ikeda M, Nagata H, Hashimoto S, Matsuzaki T, Sekimoto M, Takagi A, Monden M (2006) Low-dose oxaliplatin enhances the antitumor efficacy of paclitaxel in human gastric cancer cell lines. Digestion 74(1):19-27
11. Petrasch S, Welt A, Reinacher A, Graeven U, Konig M, Schmiegel W (1998) Chemotherapy with cisplatin and paclitaxel in patients with locally advanced, recurrent or metastatic oesophageal cancer. Br J Cancer 78(4):511-514
12. Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, Verweij J, Van Glabbeke M, van Oosterom AT, Christian MC, Gwyther SG (2000) New guidelines to evaluate the response to treatment in solid tumours: European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 92(3):205-216
13. Wassermann E, Cuvier C, Lokiec, Goldwasser F, Kalla S, Méry-Mignard D, Ouldkaci M, Besmaine A, Dupont-André G, Mahjoubi M, Marty M, Misset JL, Cvitkovic E (1999) Combination of oxaliplatin plus irinotecan in patients with gastrointestinal tumours: results of two independent phase I studies with pharmacokinetics. J Clin Oncol 17(6):1751-1759
14. André T, Bensmaine MA, Louvet C, François E, Lucas V, Desseigne F, Beerblock K, Bouché O, Carola E, Merrouche Y, Morvan F, Dupont-André G, de Gramont A (1999) Multicenter phase II study of bimonthly high-dose leucovorin, fluorouracil infusion, and oxaliplatin for metastatic colorectal cancer resistant to the same leucovorin and fluorouracil regimen. J Clin Oncol 17(11):3560-3568
15. Richards D, McCollum D, Wilfong L, Sborov M, Boehm KA, Zhan F, Asmar L (2008) Phase II trial of docetaxel and oxaliplatin in patients with advanced gastric cancer and/or adenocarcinoma of the gastroesophageal junction. Ann Oncol 19(1):104-108
16. Polee MB, Sparreboom A, Eskens FA, Hoekstra R, van de Schaaf J, Verweij J, Stoter G, van der Gaast A (2004) A phase I and pharmacokinetic study of weekly paclitaxel and carboplatin in patients with metastatic esophageal cancer. Clin Cancer Res 10(6):1928-1934
17. Polee MB, Tilanus HW, Eskens FA, Hoekstra R, Van der Burg ME, Siersema PD, Stoter G, Van der Gaast A (2003) Phase II study of neo-adjuvant chemotherapy with paclitaxel and cisplatin given every 2 weeks for patients with a resectable squamous cell carcinoma of the esophagus. Ann Oncol 14(8):1253-1257
18. Winegarden JD, Mauer AM, Otterson GA, Rudin CM, Villalona-Calero MA, Lanzotti VJ, Szeto L, Kasza K, Hoffman PC, Vokes EE (2004) A phase II study of oxaliplatin and paclitaxel in patients with advanced non-small-cell lung cancer. Ann Oncol 15(6):915-920
19. Viens P, Petit T, Yovine A, Bougnoux P, Deplanque G, Cottu PH, Delva R, Lotz JP, Belle SV, Extra JM, Cvitkovic E (2006) A phase II study of a paclitaxel and oxaliplatin combination in platinumsensitive recurrent advanced ovarian cancer patients. Ann Oncol 17(3):429-436
20. Lin RB, Fan NF, Guo ZQ, Wang XJ, Liu J, Chen L (2008) A phase II study of 5-fluorouracil/leucovorin in combination with paclitaxel and oxaliplatin as first-line treatment for patients with advanced gastric cancer. J Chemother 20(6):744-748
21. Tanaka R, Ariyama H, Qin B, Takii Y, Baba E, Mitsugi K, Harada M, Nakano S (2005) In vitro schedule-dependent interaction between paclitaxel and oxaliplatin in human cancer cell lines. Cancer Chemother Pharmacol 55(6):595-601 (Pubitemid 40674635)
22. Bekaii-Saab TS, Lui J, Chan KK, Balcerzak SP, Ivy P, Grever MR, Kraut EH (2008) A phase I and pharmacokinetic study of weekly oxaliplatin followed by paclitaxel. Clin Cancer Res 14(11):3434-3440